Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 101
Acronyms
AIDS acquired immunodeficiency syndrome
BATTLE Biomarker-based Approaches of Targeted Therapy for
Lung Cancer Elimination
BRAF Rapidly Accelerated Fibrosarcoma (B family)
CaBIG cancer Biomedical Informatics Grid
CDER Center for Drug Evaluation and Research
CDRH Center for Devices and Radiological Health
CEO chief executive officer
CGL chronic granulocytic leukemia
CITN Cancer Immunotherapy Trials Network
CMS Center for Medicare & Medicaid Services
CRADA Cooperative Research and Development Agreement
CTEP Cancer Therapy Evaluation Program
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4
DCE-MRI dynamic contrast enhanced-magnetic resonance imaging
DOJ Department of Justice
EGFR epidermal growth factor receptor
EMA European Medicines Agency
ER estrogen-receptor
101
OCR for page 102
102 COLLABORATIONS TO DEVELOP COMBINATION CANCER THERAPIES
FDA Food and Drug Administration
FNIH Foundation for the National Institutes of Health
FTC Federal Trade Commission
GSK GlaxoSmithKline
HER2 human epidermal growth factor receptor 2
HIV Human Immunodeficiency Virus
HPV human papillomavirus
IGF insulin-like growth factor
IIP instantaneous inhibitory potential
IND Investigational New Drug
IP intellectual property
IRB Institutional Review Board
I-SPY TRIAL Investigation of Serial studies to Predict Your Therapeutic
Response with Imaging And moLecular analysis
LCMV lymphocytic choriomeningitis virus
MAPK mitogen-activated protein kinase
MEK mitogen-activated protein kinase kinase
MET Methylnitronitrosoguanidine-HOS (Human
osteosarcoma) Transforming gene
MTA Material Transfer Agreement
mTORC1 mammalian target of rapamycin complex-1
NCDDG National Cooperative Drug Discovery Groups
NCI National Cancer Institute
NERF non-exclusive royalty-free
NIAID National Institute of Allergy and Infectious Diseases
NIH National Institutes of Health
NOD non-obese diabetic
OS overall survival
PathCR pathological complete response
PET positron emission tomography
PFS progression-free survival
PI3K phosphatidylinositol 3-kinase
PPTP Pediatric Preclinical Testing Program
R&D research and development
OCR for page 103
103
ACRONYMS
SOC standard of care
START Standard Terms of Agreement for Research Trial
VEGF vascular endothelial growth factor
OCR for page 104
